Today: 21 March 2026
Subscribe
Browse Category

Pharmaceuticals 29 December 2025 - 30 December 2025

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals shares fell 3.6% to $67.09 by early afternoon Tuesday, outpacing declines in biotech peers as traders positioned ahead of key January updates. The drop followed recent volatility after FDA approval of REDEMPLO, the company’s first commercial drug for familial chylomicronemia syndrome. Arrowhead plans to release interim obesity-program data and present at the J.P. Morgan Healthcare Conference in early January.
30 December 2025
··
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals shares dropped 4.2% to $107.85 in early afternoon trading Tuesday as biotech stocks broadly declined. Investors are awaiting an FDA decision on expanding Imcivree’s label, now expected by March 20, 2026. Board member Camille L. Bedrosian resigned effective immediately, according to an SEC filing. Major biotech ETFs fell over 1% while the broader market was flat.
30 December 2025
··
Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Outlook Therapeutics stock jumps ahead of FDA’s Dec. 31 Lytenava decision

Outlook Therapeutics shares closed Monday up 8.8% at $1.98, then rose about 2% in after-hours trading ahead of the FDA’s Dec. 31 decision deadline for Lytenava in wet AMD. The stock remains volatile after an August FDA rejection sent shares down nearly 70%. Trading volume has surged, with the 20-day average at 3.35 million shares. Investors are watching for the FDA’s move, which could come outside regular market hours.
30 December 2025
·
BNAI stock doubles as Brand Engagement Network lands AI pharma deal, eyes recurring fees

BNAI stock doubles as Brand Engagement Network lands AI pharma deal, eyes recurring fees

Brand Engagement Network shares surged 108.8% to $2.51 Monday after announcing a pharma AI contract expected to bring $250,000 in Q4 revenue and monthly license fees in early 2026. Volume jumped to 148.6 million shares. The company reported $102,715 in cash at Sept. 30 and $60,120 in Q3 revenue. Traders are watching if BNAI holds above $2.50 after the spike.
30 December 2025
··
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk is cutting Wegovy prices in China, with local reports citing 48% reductions for the highest doses in Yunnan and Sichuan. The move comes as the company faces a 2026 patent expiry for semaglutide and rising competition from Chinese drugmakers. Novo shares fell after the China pricing news circulated. The company did not disclose exact new prices in its statement.
30 December 2025
·
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead Sciences shares closed up 0.15% at $124.91 on Monday after Bernstein said new Medicaid drug-pricing rules would have limited impact on its HIV drug Biktarvy. Bernstein estimated less than $200 million in 2026 revenue impact for older HIV drugs Genvoya and Odefsey. Investors await more details from the Trump administration’s pricing rollout and Gilead’s update at the J.P. Morgan Healthcare Conference in January.
30 December 2025
·
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, a cancer drug developer, on Monday. The company said it expects about $0.20 in adjusted EPS dilution, split between the fourth quarter and 2026. JNJ shares ended down 0.02% at $207.56. Investors await the Jan. 21 earnings call for 2026 guidance.
30 December 2025
····
Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly shares rose 0.2% to $1,078.73 in after-hours trading Monday, with 1.64 million shares traded. Lilly Endowment Inc. disclosed the sale of 2,629 shares at $1,085.17 each, retaining over 92 million shares. Investors focused on obesity drug pricing, with Lilly and Novo Nordisk preparing pill versions and shifting to telehealth and direct-to-consumer sales. The S&P 500 fell 0.35% and the Nasdaq lost 0.5%.
29 December 2025
··
Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb stock slips today as year-end trading thins and dividend date nears

Bristol Myers Squibb shares fell 0.7% to $54.27 in thin year-end trading Monday, underperforming the broader U.S. market. Investors are watching the Jan. 2 shareholder record date for its next dividend and the Feb. 5 earnings report. Peers were mixed, with Eli Lilly up and Pfizer down. Low volumes and year-end rebalancing drove volatility, according to traders.
29 December 2025
···
Merck stock holds steady as year-end trading thins and Wall Street slips

Merck stock holds steady as year-end trading thins and Wall Street slips

Merck shares slipped 0.1% to $106.68 midday Monday, outperforming broader U.S. markets as the S&P 500 ETF fell 0.6% and the Nasdaq-100 tracker dropped 0.7%. Trading volumes remained thin ahead of Federal Reserve minutes due Tuesday. Investors await Merck’s Feb. 3 earnings call for 2026 guidance and pipeline updates. Pending U.S. home sales rose 3.3% in November, beating forecasts.
29 December 2025
··
Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly shares closed at $1,077.75, up $0.55, after ABL Bio announced it will receive $40 million upfront and a $15 million equity investment from Lilly under a research deal. The agreement follows a broader pact valued at up to $2.6 billion. Investors are watching for 2026 regulatory decisions on Lilly’s obesity drug pipeline. The S&P 500 and Dow slipped slightly on Friday.
29 December 2025
··
1 … 20 21 22 23 24 … 38

Stock Market Today

  • Corn Futures Slip Amid Strong Export Sales
    March 21, 2026, 12:35 AM EDT. Corn futures dropped 3 to 4 cents on Friday, with the front-month contracts retreating amid steady export demand. The national average cash corn price fell around 3.75 cents to $4.23 per bushel. Export sales data showed marketing-year commitments reached 67.658 million metric tons (MMT), up 30% year-on-year and tracking closely to USDA targets. Shipments totaled 43.46 MMT, outperforming the typical pace at 52% of USDA projections. The Buenos Aires Grain Exchange reported Argentina's corn harvest 13% completed. May 2026 corn prices slipped to $4.66, while December contracts edged down to $4.90. Market watchers note strong export fundamentals but a cautious tone as prices fade lightly ahead of further crop updates.
Go toTop